Keyword: Abilify

Lundbeck just officially welcomed former CEO of Millennium, Deborah Dunsire, as its own chief in September. And she's undertaking a strategic review.

Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.

Get ready for Otsuka's Abilify MyCite, the first "smart pill," to make its way to medicine cabinets, thanks to a pilot rollout with Magellan Health.

Though she has spent most of her career in oncology, Deborah Dunsire, M.D., says she doesn't plan to expand Lundbeck outside of neuroscience.

What's notable about the 10 best-selling drugs over the past 25 years? Here's a hint: Today's king is passing, and the next has a long life ahead.

Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.

U.S. government watchdogs plan to probe the FDA's orphan drug policies after Marathon's high-profile pricing scandal.

Sen. Chuck Grassley is investigating whether “unanticipated uses” of the Orphan Drug Act have helped jack up U.S. drug prices.

Years after wrapping up Abilfy marketing allegations with the U.S. Justice Department, Bristol-Myers Squibb agreed to pay $19.5 million to settle similar claims at the state level.